Not sure if she will be speaking of TPIV but if she mentions them that in itself will be a catalyst for the company. As for the Ph1 data. Patients were cancer free for 9 months. Three months prior to the trial and the six months that they were treated with the vaccine. That's great. I imagine they will try to increase the time frame during the ph 2 trial. 9 months is impressive. Also 19 out of 20 showed immune response. This is great news. They didn't mention much on toxicity either. Let's hope they collaborate with a company like ZIOP who currently has a ph 1 in breast cancer with CAR T therapy. They also have an off on switch for toxicity. The only company with this switch. It's from Intrexon and is called the Rheoswitch.
Market Data 
Markets 
AI
